20.2% Average Loss With Tirzepatide vs. 13.7% With Semaglutide
A peer-reviewed 72-week trial found greater average weight loss with tirzepatide than with semaglutide. This explains the study result—not which treatment, provider, or price is right for an individual.
Mean body-weight change was −20.2% with tirzepatide and −13.7% with semaglutide.
The between-group result was statistically significant, and participants receiving tirzepatide were more likely to reach 10%, 15%, 20%, and 25% weight-reduction thresholds. Gastrointestinal adverse events were common in both groups and were generally mild to moderate, especially during dose escalation.
Turn the study result into a better program comparison
If this result prompts you to explore GLP-1 care, compare the program details a study cannot answer: available plans, clinician access, public price terms, checkout conditions, and whether a provider fits your goals. These reviewed brands have category-matched GLP-1 offers; none participated in or is endorsed by this study.
From $49 – $129/mo · Editorial score 4.7/5
Featured value terms: semaglutide $49/mo or tirzepatide $89/mo with 12-month prepayment; $99/$129 month to month.
We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology
Study details
- Population
- 751 adults with obesity and without type 2 diabetes
- Follow-up
- 72 weeks
- Treatment comparison
- Maximum tolerated once-weekly tirzepatide (10 mg or 15 mg) compared with maximum tolerated once-weekly semaglutide (1.7 mg or 2.4 mg)
- Study design
- Phase 3b, open-label, controlled trial
A study result is not a personal treatment plan
The trial compared medicines under a defined protocol, not telehealth enrollment flows. A clinician determines whether a prescription is appropriate; insurance, local availability, dose tolerance, and follow-up requirements can materially change the care plan a person can pursue.
Compare Wegovy and Zepbound programsWhat this result does not show
- This trial compared medications, not telehealth providers, coaching programs, pharmacies, or affordability.
- The findings apply to the studied population: adults with obesity without type 2 diabetes, using the trial doses and follow-up plan.
- Average trial results are not a prediction of an individual person’s outcome, eligibility, tolerance, coverage, or prescription decision.
- The study was open-label and funded by Eli Lilly; the full paper and disclosure materials are linked at the end of this article.
Related Studies
Explore other peer-reviewed results in Evidence Watch before comparing programs or discussing options with a clinician.
Primary peer-reviewed source
Read the full paper, methodology, conflict-of-interest disclosures, and supplementary materials before drawing conclusions beyond this plain-English summary.
Read the study at New England Journal of Medicine